Pregabalin

證據等級: L5

預測適應症: 6 個

Pregabalin: From Neuropathic Pain to Tendinitis

One-Sentence Summary

Pregabalin (DrugBank DB00230) is a gabapentinoid classically used for neuropathic pain, epilepsy (adjunctive), fibromyalgia, and generalized anxiety disorder. The TxGNN model predicts it may be effective for Tendinitis, but this direction is currently supported only by 0 clinical trials and 6 publications, none of which directly study tendon pathology.

Quick Overview

Item	Content
Original Indication	Not captured in this evidence pack (no NZ license/indication text available); pregabalin is globally established for neuropathic pain, epilepsy (adjunct), fibromyalgia, and generalized anxiety disorder
Predicted New Indication	Tendinitis
TxGNN Prediction Score	99.71%
Evidence Level	L4
New Zealand Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on well-established pharmacology, pregabalin binds the α2δ-1 subunit of voltage-gated calcium channels, reducing presynaptic release of excitatory neurotransmitters (glutamate, substance P), which underlies its clinical use in neuropathic pain and as an analgesic/anticonvulsant adjunct.

The literature retrieved for tendinitis consists mainly of RCTs evaluating pregabalin as a perioperative, opioid-sparing analgesic adjunct after arthroscopic rotator cuff repair — not studies of tendon inflammation, degeneration, or repair biology. The evidence pack's own mechanistic assessment is explicit on this point: current literature reflects symptomatic pain-control extrapolation rather than any disease-specific effect on tendon pathology, and there is no evidence pregabalin alters tendinopathy mechanisms.

Given the absence of a specific mechanistic rationale and of any tendinitis-focused trial, the high TxGNN score most likely reflects graph-structural proximity between "pain/nerve" and "musculoskeletal" nodes in the knowledge graph rather than a validated pharmacological hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32839073	2021	RCT (perioperative analgesia)	Journal of Orthopaedic Science	Retrospective cohort on analgesic efficacy and opioid-sparing effect of pregabalin after arthroscopic rotator cuff repair
34052386	2022	RCT (perioperative analgesia)	Arthroscopy	Perioperative oral pregabalin produced pain scores comparable to interscalene brachial plexus block after rotator cuff repair
37051935	2023	Case report	Pain Practice	Posterior femoral cutaneous nerve impingement from hamstring tendonitis post-marathon; not a pregabalin efficacy study
41017607	2025	Case report	Praxis	Fluoroquinolone-associated tendinopathy/disability case; pregabalin not the study drug
40818536	2025	Editorial commentary	Arthroscopy	Commentary on piriformis syndrome diagnosis and surgical management; not related to pregabalin
39703364	2024	Preclinical (animal extract study)	Advances in Pharmacological and Pharmaceutical Sciences	Plant extract (not pregabalin) attenuates vincristine-induced peripheral neuropathy in rats

New Zealand Market Information

Pregabalin currently has no market authorization on record in this evidence pack (0 licenses); market status is "Not Marketed."

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L4 with zero clinical trials and no literature specific to tendon inflammation or repair — the retrieved studies address perioperative pain control after rotator cuff surgery, not tendinitis treatment itself, so the TxGNN signal cannot currently be distinguished from graph-structural noise.

To proceed, the following is needed:

TFDA/NZ regulatory package insert data (warnings, contraindications) — currently a Blocking data gap
Confirmed mechanism of action (DrugBank query) — currently a High-severity data gap
A tendinitis- or tendinopathy-specific preclinical or clinical study evaluating pregabalin's effect on inflammatory/repair pathways, not just pain scores
If pursued, a dedicated trial design (not opioid-sparing surrogate outcomes)

Appendix: Other TxGNN-Predicted Indications in This Evidence Pack

This evidence pack (TW-DB00230-multi) scored six candidate indications for pregabalin. Evidence strength varies considerably and does not track TxGNN rank order — notably, migraine disorder (ranked 5th by score) has substantially stronger clinical evidence than the top-ranked tendinitis prediction:

Disease	TxGNN Score	Evidence Level	Decision Stage	Recommendation
Tendinitis	99.71%	L4	S0	Hold
Myositis fibrosa	99.71%	L5	S0	Hold
Idiopathic granulomatous myositis	99.71%	L5	S0	Hold
Inclusion body myositis	99.52%	L5	S0	Hold
Migraine disorder	99.47%	L2	S2	Research Question
Migraine with brainstem aura	99.43%	L4	S0	Hold

Migraine disorder is backed by a Cochrane systematic review (PMID 23797674/23797675), a 2024 JAMA Network Open network meta-analysis, and multiple pediatric RCTs (PMID 37637787, 26024701), plus a mechanistic rationale (α2δ-1-mediated inhibition of cortical spreading depression) directly relevant to migraine pathophysiology — unlike the tendinitis and myositis predictions, whose supporting literature is largely incidental or graph-structural. If this candidate pool is being triaged for further work, migraine disorder — not tendinitis — is the stronger near-term candidate and warrants a separate evaluation report at decision stage S2.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.